A citation-based method for searching scientific literature

Gautam Borthakur, Giovanni Martinelli, Emmanuel Raffoux, Patrice Chevallier, Jörg Chromik, Andrew Lithio, Claire L Smith, Eunice Yuen, Gerard Joseph Oakley, Karim A Benhadji, Daniel J DeAngelo. Cancer 2021
Times Cited: 10







List of co-cited articles
199 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.
Andrew P Weng, Adolfo A Ferrando, Woojoong Lee, John P Morris, Lewis B Silverman, Cheryll Sanchez-Irizarry, Stephen C Blacklow, A Thomas Look, Jon C Aster. Science 2004
60

Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition.
Roger A Habets, Charles E de Bock, Lutgarde Serneels, Inge Lodewijckx, Delphine Verbeke, David Nittner, Rajeshwar Narlawar, Sofie Demeyer, James Dooley, Adrian Liston,[...]. Sci Transl Med 2019
53
50

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer.
C Massard, A Azaro, J-C Soria, U Lassen, C Le Tourneau, D Sarker, C Smith, U Ohnmacht, G Oakley, B K R Patel,[...]. Ann Oncol 2018
76
50

FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.
Jennifer O'Neil, Jonathan Grim, Peter Strack, Sudhir Rao, Deanne Tibbitts, Christopher Winter, James Hardwick, Markus Welcker, Jules P Meijerink, Rob Pieters,[...]. J Exp Med 2007
507
40

The Varied Roles of Notch in Cancer.
Jon C Aster, Warren S Pear, Stephen C Blacklow. Annu Rev Pathol 2017
326
40

TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms.
L W Ellisen, J Bird, D C West, A L Soreng, T C Reynolds, S D Smith, J Sklar. Cell 1991
40

An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.
Birgit Knoechel, Justine E Roderick, Kaylyn E Williamson, Jiang Zhu, Jens G Lohr, Matthew J Cotton, Shawn M Gillespie, Daniel Fernandez, Manching Ku, Hongfang Wang,[...]. Nat Genet 2014
244
40

Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.
Pedro J Real, Valeria Tosello, Teresa Palomero, Mireia Castillo, Eva Hernando, Elisa de Stanchina, Maria Luisa Sulis, Kelly Barnes, Catherine Sawai, Irene Homminga,[...]. Nat Med 2009
330
40

A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer.
Sagar Sardesai, Mohamed Badawi, Ewa Mrozek, Evan Morgan, Mitch Phelps, Julie Stephens, Lai Wei, Mahmoud Kassem, Yonghua Ling, Maryam Lustberg,[...]. Invest New Drugs 2020
14
40

A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014.
Wells A Messersmith, Geoffrey I Shapiro, James M Cleary, Antonio Jimeno, Arvind Dasari, Bo Huang, M Naveed Shaik, Rossano Cesari, Xianxian Zheng, Jennifer M Reynolds,[...]. Clin Cancer Res 2015
136
40

Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer.
Analía Azaro, Capucine Baldini, Jordi Rodon, Jean-Charles Soria, Eunice Yuen, Andrew Lithio, Gerard Oakley, Karim A Benhadji, Christophe Massard. Invest New Drugs 2021
9
44


Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma.
Mark J Kiel, Thirunavukkarasu Velusamy, Bryan L Betz, Lili Zhao, Helmut G Weigelin, Mark Y Chiang, David R Huebner-Chan, Nathanael G Bailey, David T Yang, Govind Bhagat,[...]. J Exp Med 2012
202
30

Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy.
Elisabeth Silkenstedt, Fabian Arenas, Berta Colom-Sanmartí, Sílvia Xargay-Torrent, Morihiro Higashi, Ariadna Giró, Vanina Rodriguez, Patricia Fuentes, Walter E Aulitzky, Heiko van der Kuip,[...]. J Exp Clin Cancer Res 2019
14
30

Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.
Teresa Palomero, Maria Luisa Sulis, Maria Cortina, Pedro J Real, Kelly Barnes, Maria Ciofani, Esther Caparros, Jean Buteau, Kristy Brown, Sherrie L Perkins,[...]. Nat Med 2007
672
30

γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer.
H Mizugaki, J Sakakibara-Konishi, Y Ikezawa, J Kikuchi, E Kikuchi, S Oizumi, T P Dang, M Nishimura. Br J Cancer 2012
40
30

A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors.
Toshihiko Doi, Masaomi Tajimi, Joji Mori, Hiroya Asou, Koichi Inoue, Karim A Benhadji, Yoichi Naito. Invest New Drugs 2021
7
42


Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.
Ping Wei, Marlena Walls, Ming Qiu, Richard Ding, Robert H Denlinger, Anthony Wong, Kosta Tsaparikos, Jitesh P Jani, Natilie Hosea, Michelle Sands,[...]. Mol Cancer Ther 2010
146
30


Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia.
Jeremy B Samon, Mireia Castillo-Martin, Michael Hadler, Alberto Ambesi-Impiobato, Elisabeth Paietta, Janis Racevskis, Peter H Wiernik, Jacob M Rowe, John Jakubczak, Sophia Randolph,[...]. Mol Cancer Ther 2012
83
30

Targeting Notch in oncology: the path forward.
Samarpan Majumder, Judy S Crabtree, Todd E Golde, Lisa M Minter, Barbara A Osborne, Lucio Miele. Nat Rev Drug Discov 2021
62
30

Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency.
Wan-Ching Yen, Marcus M Fischer, Fumiko Axelrod, Christopher Bond, Jennifer Cain, Belinda Cancilla, William R Henner, Rene Meisner, Aaron Sato, Jalpa Shah,[...]. Clin Cancer Res 2015
168
30

A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.
Zishuo Ian Hu, Johanna C Bendell, Andrea Bullock, Noelle K LoConte, Hassan Hatoum, Paul Ritch, Hugo Hool, Joseph W Leach, James Sanchez, Davendra P S Sohal,[...]. Cancer Med 2019
31
30

Top Notch Targeting Strategies in Cancer: A Detailed Overview of Recent Insights and Current Perspectives.
Gillian Moore, Stephanie Annett, Lana McClements, Tracy Robson. Cells 2020
56
30

Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.
Di Cui, Jinlu Dai, Jill M Keller, Atsushi Mizokami, Shujie Xia, Evan T Keller. Clin Cancer Res 2015
58
30

Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.
Fiona Blackhall, Kevin Jao, Laurent Greillier, Byoung Chul Cho, Konstantin Penkov, Noemi Reguart, Margarita Majem, Kristiaan Nackaerts, Konstantinos Syrigos, Karin Hansen,[...]. J Thorac Oncol 2021
40
30

A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.
David C Smith, Rashmi Chugh, Amita Patnaik, Kyriakos P Papadopoulos, Min Wang, Ann M Kapoun, Lu Xu, Jakob Dupont, Robert J Stagg, Anthony Tolcher. Invest New Drugs 2019
32
30

Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3.
Kang Li, Yucheng Li, Wenjuan Wu, Wendy R Gordon, David W Chang, Mason Lu, Shane Scoggin, Tihui Fu, Long Vien, Gavin Histen,[...]. J Biol Chem 2008
149
30

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.
Mark J McKeage, Dusan Kotasek, Ben Markman, Manuel Hidalgo, Michael J Millward, Michael B Jameson, Dean L Harris, Robert J Stagg, Ann M Kapoun, Lu Xu,[...]. Target Oncol 2018
34
30

A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma.
Natalie Cook, Bristi Basu, Donna-Michelle Smith, Aarthi Gopinathan, Jeffry Evans, William P Steward, Daniel Palmer, David Propper, Balaji Venugopal, Mirela Hategan,[...]. Br J Cancer 2018
56
30

Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
Anthony W Tolcher, Wells A Messersmith, Stanislaw M Mikulski, Kyriakos P Papadopoulos, Eunice L Kwak, Darlene G Gibbon, Amita Patnaik, Gerald S Falchook, Arvind Dasari, Geoffrey I Shapiro,[...]. J Clin Oncol 2012
180
30

Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).
Shivaani Kummar, Geraldine O'Sullivan Coyne, Khanh T Do, Baris Turkbey, Paul S Meltzer, Eric Polley, Peter L Choyke, Robert Meehan, Rasa Vilimas, Yvonne Horneffer,[...]. J Clin Oncol 2017
93
30

Gamma Secretase Inhibitors in Cancer: A Current Perspective on Clinical Performance.
Tyler R McCaw, Evelyn Inga, Herbert Chen, Renata Jaskula-Sztul, Vikas Dudeja, James A Bibb, Bin Ren, J Bart Rose. Oncologist 2021
19
30

A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours.
Kyaw L Aung, Anthony B El-Khoueiry, Karen Gelmon, Ben Tran, Gaurav Bajaj, Bing He, Tian Chen, Lili Zhu, Sharath Poojary, Shashwati Basak,[...]. Invest New Drugs 2018
16
30

A phase II study of RO4929097 in metastatic colorectal cancer.
Jonathan R Strosberg, Timothy Yeatman, Jill Weber, Domenico Coppola, Michael J Schell, Gang Han, Khaldoun Almhanna, Richard Kim, Tiffany Valone, Helen Jump,[...]. Eur J Cancer 2012
96
30

A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma.
David M Peereboom, Xiaobu Ye, Tom Mikkelsen, Glenn J Lesser, Frank S Lieberman, H Ian Robins, Manmeet S Ahluwalia, Andrew E Sloan, Stuart A Grossman. Neurosurgery 2021
9
33

Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
Sylvia M Lee, James Moon, Bruce G Redman, Tarek Chidiac, Lawrence E Flaherty, Yuanyuan Zha, Megan Othus, Antoni Ribas, Vernon K Sondak, Thomas F Gajewski,[...]. Cancer 2015
65
30

Notch signaling: cell fate control and signal integration in development.
S Artavanis-Tsakonas, M D Rand, R J Lake. Science 1999
30

Notch2 receptor signaling controls functional differentiation of dendritic cells in the spleen and intestine.
Kanako L Lewis, Michele L Caton, Milena Bogunovic, Melanie Greter, Lucja T Grajkowska, Dennis Ng, Apostolos Klinakis, Israel F Charo, Steffen Jung, Jennifer L Gommerman,[...]. Immunity 2011
315
20

Oncogenic Notch signaling in T-cell and B-cell lymphoproliferative disorders.
Mark Y Chiang, Vedran Radojcic, Ivan Maillard. Curr Opin Hematol 2016
24
20

The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.
Luca Arcaini, Davide Rossi, Marco Lucioni, Marta Nicola, Alessio Bruscaggin, Valeria Fiaccadori, Roberta Riboni, Antonio Ramponi, Virginia V Ferretti, Stefania Cresta,[...]. Haematologica 2015
51
20

Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development.
Toshiki Saito, Shigeru Chiba, Motoshi Ichikawa, Atsushi Kunisato, Takashi Asai, Kiyoshi Shimizu, Tomoyuki Yamaguchi, Go Yamamoto, Sachiko Seo, Keiki Kumano,[...]. Immunity 2003
414
20

Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells.
Marica Pinazza, Margherita Ghisi, Sonia Minuzzo, Valentina Agnusdei, Gianluca Fossati, Vincenzo Ciminale, Laura Pezzè, Yari Ciribilli, Giorgia Pilotto, Carolina Venturoli,[...]. Oncogene 2018
19
20

NOTCH2 mutations in marginal zone lymphoma.
Gunhild Trøen, Iwona Wlodarska, Abdirashid Warsame, Silvia Hernández Llodrà, Christiane De Wolf-Peeters, Jan Delabie. Haematologica 2008
42
20


Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells.
Mónica López-Guerra, Sílvia Xargay-Torrent, Patricia Fuentes, Jocabed Roldán, Blanca González-Farré, Laia Rosich, Elisabeth Silkenstedt, María J García-León, Eriong Lee-Vergés, Neus Giménez,[...]. Oncogene 2020
15
20

Notch3 contributes to T-cell leukemia growth via regulation of the unfolded protein response.
Maria Valeria Giuli, Giulia Diluvio, Eugenia Giuliani, Giulia Franciosa, Laura Di Magno, Maria Gemma Pignataro, Luca Tottone, Carmine Nicoletti, Zein Mersini Besharat, Giovanna Peruzzi,[...]. Oncogenesis 2020
10
20

Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma.
Suk-young Lee, Keiki Kumano, Kumi Nakazaki, Masashi Sanada, Akihiko Matsumoto, Go Yamamoto, Yasuhito Nannya, Ritsuro Suzuki, Satoshi Ota, Yasunori Ota,[...]. Cancer Sci 2009
117
20

Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies.
P Bernasconi-Elias, T Hu, D Jenkins, B Firestone, S Gans, E Kurth, P Capodieci, J Deplazes-Lauber, K Petropoulos, P Thiel,[...]. Oncogene 2016
55
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.